Skip to main navigation
  • Skip to content
  • Skip to primary sidebar
Back to the Corporate Site
Veloxis

Back to the Corporate Site

Investor Relations

IR Menu

  • News & Releases
  • Download Center
  • Calendar
  • Corporate Governance
    • Governance Documents
    • Risk Management
    • Reporting Compliance
    • Violations and Concerns
    • Whistleblower Policy
    • Whistleblowing Guidelines
  • Financial Information
    • Outlook
  • Stock Information
    • Historic Stock Lookup
    • Investment Calculator
    • Order Depth and Latest Trades
    • Analyst Coverage
  • General Meetings

Press Releases

Veloxis Increases Share Capital in Connection with Exercise of Warrants

December 1, 2017 at 6:00 AM EST
2017.12.01 Company Release 24 - Veloxis Increases Share Capital in Connection with Exercise of Warrants.pdf 240.1 KB

Company Release no. 24/2017

 

To: NASDAQ Copenhagen A/S                                  Copenhagen, Denmark, 01 December 2017

  

Veloxis Increases Share Capital in Connection with Exercise of Warrants

 

Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased by 1,444,900 new shares with a nominal value of DKK 0.10 each corresponding to nominally DKK 144,490 as a consequence of the exercise of warrants by former employees of the Company granted under the Company's warrant program.

As a result of the employee's investment in the Company proceeds to Veloxis Pharmaceuticals A/S from the capital increase amounts to DKK 520,164.

The subscription price for the new shares is DKK 0.36 per share of nominal DKK 0.10.

The new shares will be listed on NASDAQ Copenhagen following registration of the capital increase with the Danish Business Authority, upon which the share capital of Veloxis Pharmaceuticals A/S will be DKK 171,243,853.10 divided into shares of DKK 0.10 each.

Each share of nominal DKK 0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S.  The new shares give rights to dividend and other rights from the time of registration of the capital increase with the Danish Business Authority.

  

For more information, please contact:

Craig A. Collard            

President & CEO                      

Phone: +1 919 591 3090                     

Email: cac@veloxis.com                      

 

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals, Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the Company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs.  The Company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit www.veloxis.com.

Shareholder Portal

Enter Veloxis portal for existing shareholders.

flagDA  PÅ DANSK flagUK  IN ENGLISH

STOCK QUOTE

Change
Volume
Year High
Year Low
Feb 19, 2019 6:16 PM CET Currency in DKK.
Copyright West LLC.
Minimum 15 minutes delayed.
View More

Upcoming Events

Release of 2018 Annual Report
Feb 27, 2019
2019 Annual General Meeting
Apr 3, 2019

Latest News & Releases

Jan 03, 2019
Mark Hensley Promoted to Chief Commercial Officer of Veloxis Pharmaceuticals
Dec 31, 2018
Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program

View All

© 2019 All rights reserved. Veloxis Pharmaceuticals Inc. ENV-18-090.0 06/18

info@veloxis.com | 1-844-VELOXIS (835-6947), Monday-Friday, 9AM-7PM ET

Sitemap | Contact | Privacy Policy | Disclaimer